- Home
- Companies
- canada nova scotia
- liquid biopsy
Show results for
Refine by
Liquid Biopsy Suppliers Serving Nova Scotia
51 companies found
based inXiamen, CHINA
Amoy Diagnostics Co., Ltd. (AmoyDx) is an R&D based diagnostic company, focusing on molecular diagnostics for oncology precision medicine. With completely independent intellectual property rights of ADx-ARMS®, Super-ARMS®, ddCapture® and ADx-HANDLE® ...
based inBerlin, GERMANY
We revolutionize the way of cancer diagnostics using our unique, proprietary DNA methylation biomarker technology. Epigenomics develops and commercializes patient-friendly, blood-based diagnostic tests across multiple cancer indications with high ...
Colorectal cancer is curable in about 90% of cases if detected early. Nevertheless, this disease is one of the most frequent causes of cancer-related deaths in the industrialized world. Regular screening can prevent colorectal cancer. Epi ...
based inManchester, UNITED KINGDOM
Yourgene Health is a leading international molecular diagnostics group with an integrated portfolio of technologies and services to enable genomic medicine. Our mission to enable scientific advances to positively impact human health remains at the ...
based inGuildford, UNITED KINGDOM
Datar Cancer Genetics is a leader in developing blood-based diagnostics that can detect cancer early, offer non-invasive investigations for better treatment options, and track the progression of the disease or its recurrence. We believe that ...
Cancertrack is an advanced non-invasive blood test which provides real time intel on the status of a malignancy from a safe, simple and quick blood draw. Cancertrack profiles molecular features in circulating tumor DNA and circulating tumor RNA and ...
based inAlameda, CALIFORNIA (USA)
Fluxion delivers advanced solutions that transform complex cell-based and cell-free assays. Leading labs across the globe rely on Fluxion's instruments, kits, and lab services to research novel biology, accelerate drug discovery, and tailor ...
Fluxion provides analytical services for a diverse range of liquid biopsy and CTC applications. Our Lab Services programs enables you to get results quickly and efficiently using Fluxion’s state-of-the-art ...
based inPleasanton, CALIFORNIA (USA)
Anchor Molecular is a life science diagnostics company specializing in the development of best-in-class quality controls, reference materials, and reagents for liquid biopsy assays. We focus on liquid biopsy cancer diagnostic test based on cell-free ...
The Extraction Sensitivity Controls can help by monitoring plasma cfDNA loss, determining how low the absolute plasma cfDNA number of copies can be reliably extracted, and standardizing QC workflow for plasma cfDNA extraction process. Two extraction ...
based inValladolid, SPAIN
Founded in 2010, AMADIX is a leading molecular diagnostics company, focused on liquid biopsy, developing innovative diagnostic tests for early cancer detection in blood. Our mission is to extend people’s lives by developing disruptive technologies ...
It can also be used as a tool for a high-risk screening population in combination with Low Dose Computed Tomography (LDCT). DiagnoLung identifies and measures proteins which are differentially expressed in blood samples of individuals with Lung ...
based inPalo Alto, CALIFORNIA (USA)
Lucence is a precision oncology company committed to bringing clarity to cancer care. Lucence makes ultrasensitive non-invasive liquid biopsy tests to provide doctors and their patients life-changing information to enable earlier detection and ...
AmpliMark is the foundational technology behind Lucence’s liquid biopsy tests. AmpliMark uses unique molecular barcodes in this error-correction technology. It is designed to improve detection of multiple ...
based inNew Taipei City, TAIWAN
Blue-Ray Biotech aims to provide global biotechnology researchers with innovative and reliable products to further accelerate the development of biotechnology. We have devoted ourselves to developing, manufacturing, and marketing cutting-edge ...
based inCambridge, UNITED KINGDOM
Owlstone Medical is developing a breathalyzer for disease. With a goal to find ways to improve non-invasive diagnostics for respiratory diseases, liver diseases, cancer, digestive health and other conditions. Our mission is to save 100,000 lives and ...
based inPalo Alto, CALIFORNIA (USA)
Nirmidas Biotech was founded in September of 2013. We are a member of the Janssen Labs (JLABS) and QB3 programs, the Stanford StartX Med Program, and the MIT Industrial Liaison Program (MIT ILP). We are also a StartX Med COVID-19 Task Force Company ...
based inNotting Hill, AUSTRALIA
INOVIQ Ltd (ASX:IIQ) (INOVIQ) is developing and commercialising an innovative portfolio of diagnostic and exosome-based solutions for the earlier detection, diagnosis, prognosis and monitoring of cancer and other diseases to improve patient outcomes ...
EXO-NET RUO - a pan-exosome capture tool for isolation of exosomes from body fluids including plasma, urine, and saliva. Exosomes are small membrane-enclosed vesicles actively secreted by most cells into biological fluids including serum, plasma, ...
based in, MASSACHUSETTS (USA)
Thermo Scientific instruments, equipment, software, services and consumables empower scientists to solve for complex analytical challenges in pharmaceutical, biotechnology, academic, government, environmental and industrial research, as well as the ...
based inHallbergmoos, GERMANY
Xpedite Diagnostics is at the forefront of advancing molecular diagnostics to the point-of-care level, focusing on revolutionizing the nucleic acid extraction process. The company's groundbreaking SwiftX™ technology eliminates the reliance on ...
The SwiftX™ cfDNA Extraction Kit is designed for efficient extraction of cell-free DNA (cfDNA) from large volumes of serum, plasma, and urine samples in under 15 minutes. This kit is particularly beneficial for applications in oncology ...
based inFrederick, MARYLAND (USA)
In 2019, ProMedDx and GLAS Bio were acquired by Precision for Medicine, part of Precision Medicine Group. This new combination significantly bolstered the selection, scientific prowess and solutions available to customers from a single partner. With ...
Experienced global network of principal investigators, labs, and logistics experts available to source tissues for your research program. ...
based inDoylestown, PENNSYLVANIA (USA)
Incorporated in PA in 2011, our MISSION is to translate our circulating cell-free DNA (cfDNA) in urine technology into improved cancer screening and management by liquid biopsy towards our VISION of decreased global cancer mortality. Our proprietary ...
based inCincinnati, OHIO (USA)
Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic and life science products. We are dedicated to developing and delivering better solutions that give ...
based inLondon, UNITED KINGDOM
Getting ahead of cancer is crucial no matter where people are in their cancer journey. From earlier cancer detection to treatment guidance and monitoring, we are helping people get the answers they need to make more informed decisions across the ...
based inSint-Denijs Westrem, BELGIUM
We are a commercial stage medical device company developing the alfapump® platform for the treatment of fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective. The alfapump®, is a fully ...
Ascites is also a common complication of certain late-stage cancers due to fluid build-up in the peritoneal cavity from a number of causes including draining of the lymph system. While life expectancy for many cancer patients with malignant ascites ...
based inDaejeon, SOUTH KOREA
PANAGENE have been supplying Peptide Nucleic Acid (PNA) worldwide and exclusively since 2006 based on our unique invention of efficient synthesis of PNA with high purity, and nowadays we are possessing the best knowledge on PNA and the largest ...
NRAS mutation is found in several cancers such as melanoma (13~25%), colorectal cancer (1~6%), lung cancer (1%), thyroid cancer (7%) and hepatocellular carcinoma (10%). It is know that the drug response against colorectal cancer medicine such as ...